Skip to main
SLNO

Soleno Therapeutics (SLNO) Stock Forecast & Price Target

Soleno Therapeutics (SLNO) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Soleno Therapeutics has demonstrated strong financial performance, with a preliminary unaudited net revenue for full-year 2025 projected between $90 million and $92 million, significantly surpassing previous forecasts. The company's product VYKAT XR is expected to generate up to $2.3 billion in peak annual sales in the U.S., with initial sales figures since its launch in 2Q25 already ranging from $189 million to $191 million. Additionally, Soleno maintains a robust financial position with an anticipated cash balance of approximately $500 million by the end of 2025, providing the company with ample resources for future growth initiatives, including potential mergers and acquisitions.

Bears say

Soleno Therapeutics Inc. faces a negative outlook primarily due to several financial and operational risks, including market access and reimbursement issues that may hinder the uptake of its product candidate, DCCR. The company is also anticipating earlier-than-expected generic erosion of the DCCR franchise, which could diminish potential revenue streams. Additionally, Soleno's inability to effectively optimize DCCR's value outside the U.S. further contributes to concerns about its long-term profitability and market position.

Soleno Therapeutics (SLNO) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Soleno Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Soleno Therapeutics (SLNO) Forecast

Analysts have given Soleno Therapeutics (SLNO) a Buy based on their latest research and market trends.

According to 10 analysts, Soleno Therapeutics (SLNO) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $112.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $112.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Soleno Therapeutics (SLNO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.